Concepedia

Vernon Alford

VA

Statistics

Publications

11

Citations

289

H-Index

11

Active since

2000

Affiliations

Johnson & Johnson (United States)(Current)

Janssen (United States)

AstraZeneca (United States)

Vernon Alford is an author at Johnson & Johnson (United States) specializing in pharmacology, medicinal chemistry, and drug discovery.

Publications per year

2000–2013

11

Publications

11

Design and Characterization of Optimized Adenosine A<sub>2A</sub>/A<sub>1</sub> Receptor Antagonists for the Treatment of Parkinson's Disease

Brian C. Shook, Stefanie Rassnick, Nathaniel Wallace et al. · Journal of Medicinal Chemistry · 2012 · 46 citations · Full text

, , +12

The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. part 1

Chris A. Veale, Vernon Alford, David Aharony et al. · Bioorganic & Medicinal Chemistry Letters · 2000 · 44 citations · Full text

, , +9

Synthesis and SAR of potent and selective androgen receptor antagonists: 5,6-Dichloro-benzimidazole derivatives

Raymond A. Ng, Jihua Guan, Vernon Alford et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 38 citations

, , +11

Synthesis of potent and tissue-selective androgen receptor modulators (SARMs): 2-(2,2,2)-Trifluoroethyl-benzimidazole scaffold

Raymond A. Ng, James C. Lanter, Vernon Alford et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 35 citations · Full text

, , +13

2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists

Raymond A. Ng, Jihua Guan, Vernon Alford et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 27 citations

, , +10

1–5 of 11